The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30 mg and 60 mg, in the morning with ranitidine 300 mg at bedtime. (p=0026) also recorded greater relief of night time pain in the diary cards during the first seven days of treatment than those on ranitidine. Patients on lansoprazole 60 mg reported significantly better pain relief at their two week visit compared with those receiving ranitidine (p=0 007). There were no differences between treatment groups in the occurrence or pattern of adverse drug reactions during the trial. It is concluded that for patients with duodenal ulcer, lansoprazole 30 mg or 60 mg is associated with faster ulcer healing and better symptom relief than ranitidine 300 mg at bedtime. There were no significant differences between lansoprazole 30 mg and 60 mg. These data indicate that lansoprazole should be used at a once daily dose of 30 mg for the treatment of duodenal ulcer.
Abstract
The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30 mg and 60 mg, in the morning with ranitidine 300 mg at bedtime. Two hundred and eighty nine patients were enrolled over a 20 month period in a double blind randomised paraliel group comparative study set in outpatient endoscopy units of six United Kingdom medical centres. Patients were randomised to receive lansoprazole 30 mg in the morning (n=95), 60 mg in the morning (n=96), or ranitidine 300 mg at bedtime (n=98) for four weeks. Efficacy was assessed by gastroscopy at study entry and after two and four weeks of treatment. Symptom relief was monitored by patient diaries and physician review at two and four weeks. Both doses of lansoprazole resulted in significantly greater ulcer healing than ranitidine after two and four weeks. Respective healing rates on lansoprazole 30 mg, 60 mg, and ranitidine 300 mg were 78%, 80%, and 60% after two weeks and 93%, 97%, and 81% after four weeks. Patients on lansoprazole 30 mg (p=0O002) and lansoprazole 60 mg (p=0026) also recorded greater relief of night time pain in the diary cards during the first seven days of treatment than those on ranitidine. Patients on lansoprazole 60 mg reported significantly better pain relief at their two week visit compared with those receiving ranitidine (p=0 007). There were no differences between treatment groups in the occurrence or pattern of adverse drug reactions during the trial. It is concluded that for patients with duodenal ulcer, lansoprazole 30 mg or 60 mg is associated with faster ulcer healing and better symptom relief than ranitidine 300 mg at bedtime. There were no significant differences between lansoprazole 30 mg and 60 mg. The primary end point was cumulative ulcer healing in evaluable patients (all those having an endoscopy at a particular visit). This can be regarded as a pragmatic approach.8 In addition a secondary 'per protocol' analysis was performed, in those patients who met the eligibility criteria (patient selection) and evaluability criteria (repeat endoscopy within three days of specified time having taken 75% of treatment) as specified'in the protocol. Healing rates at weeks 2 and 4 were compared across treatment groups using a 3x2 x2. If this was at or near the 5% significance value, pairwise comparisons between groups were made using the X2 test (with continuity correction) or Fisher's exact test, and 95% confidence intervals were constructed for each pairwise difference.9 Multivariate logistic Results Two hundred and eighty nine patients were enroled into the study over a period of 20 months. One hundred and eighty were smokers and 109 were non or former smokers. Table I shows the distribution of patient characteristics across the three treatment groups. Age, sex, smoking, and alcohol use seem to be relatively well balanced across the treatment groups. Any effect these factors may have had on healing rates were examined using logistic regression analysis.
ULCER HEALING
The primary analysis showed a statistically significant difference across treatment groups both at week 2 (p=0 005) and week 4 (p=0 001). Pairwise comparisons showed that the superiority of healing rates with both doses number of patients receiving non-steroidal antiinflammatory drugs in each group was too small to include in the model. Although the study was stratified for smoking habits as a possible prognostic factor this was not confirmed in this study. This was probably due to similar healing rates for smokers and non former smokers receiving either dose of lansoprazole (Fig 1) . The analysis showed a difference in healing rates across centres in the per protocol analysis but not the evaluable patient group. All treatments were equally affected, however, (treatment/centre interactions not significant, p=0 5 1) daytime pain did not reach statistical significance (p=0 37).
ANTACID USE
The degree of pain relief was reflected in the consumption of antacids. There was a statistically significant (p=0-0 18) difference between the three treatment groups in the proportion of days on which antacids were taken. Patients receiving lansoprazole 30 mg took antacids on 12-7% (median) of days. Those on lansoprazole 60 mg took them on 15-7% of days, and those on ranitidine 25 5% of days. Pairwise comparisons showed the difference between those receiving lansoprazole 30 mg and those receiving ranitidine 300 mg was significant (p=0005), while that between those receiving lansoprazole 60 mg and those receiving ranitidine approached statistical significance (p=0 06). There was no difference between the two lansoprazole groups (p=0973). 
